Link to this page
National Cancer Institute Thesaurus
Preferred Name | Erlotinib | |
Synonyms |
ERLOTINIB Erlotinib erlotinib |
|
Definitions |
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65530 |
|
CAS_Registry |
183321-74-6
|
|
CHEBI_ID |
CHEBI:114785
|
|
Chemical_Formula |
C22H23N3O4
|
|
code |
C65530
|
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc
|
|
DEFINITION |
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
|
|
Display_Name |
Erlotinib
|
|
FDA_UNII_Code |
J4T82NDH7E
|
|
FULL_SYN |
ERLOTINIB Erlotinib erlotinib
|
|
Has_Salt_Form | ||
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Erlotinib
|
|
Legacy Concept Name |
Erlotinib_Base
|
|
Maps_To |
Erlotinib
|
|
Preferred_Name |
Erlotinib
|
|
prefixIRI |
Thesaurus:C65530
|
|
Semantic_Type |
Pharmacologic Substance
|
|
UMLS_CUI |
C1135135
|
|
subClassOf |
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |